Cargando…

Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study

BACKGROUND AND AIMS: Irritant diaper dermatitis (IDD) is very common in infants and usually managed by the caregiver. Dexpanthenol‐containing ointment (DCO) is a decades‐long established product that has demonstrated efficacy and tolerability in the treatment and prevention of infant IDD in controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Peltier, Erwan, de Salvo, Raffaella, Ehret, Andreas, Trapp, Sonja, Lakomsky, Didier, El Shazly, Maged A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817493/
https://www.ncbi.nlm.nih.gov/pubmed/36620516
http://dx.doi.org/10.1002/hsr2.1033
_version_ 1784864763497414656
author Peltier, Erwan
de Salvo, Raffaella
Ehret, Andreas
Trapp, Sonja
Lakomsky, Didier
El Shazly, Maged A.
author_facet Peltier, Erwan
de Salvo, Raffaella
Ehret, Andreas
Trapp, Sonja
Lakomsky, Didier
El Shazly, Maged A.
author_sort Peltier, Erwan
collection PubMed
description BACKGROUND AND AIMS: Irritant diaper dermatitis (IDD) is very common in infants and usually managed by the caregiver. Dexpanthenol‐containing ointment (DCO) is a decades‐long established product that has demonstrated efficacy and tolerability in the treatment and prevention of infant IDD in controlled clinical settings. The aim of this study was to evaluate the effectiveness of DCO in the treatment of infant IDD from the perspective of the caregiver by collecting data not explored in clinical trials, such as infant quality of life and the speed of action. METHODS: A retrospective observational real‐world data (RWD) study was conducted with French adult caregivers who had used a DCO to treat IDD in their infants within the past 6 months and consented to participate to the study completed a web‐based survey answering questions regarding the severity of their infants' symptoms (intensity/extent of redness and discomfort, rated using Likert scales) before and after DCO application. The speed of onset of symptom relief and product acceptability were also collected. RESULTS: A total of 500 caregivers of 564 infants completed the survey. Of these, 80% reported that DCO visibly treats IDD. In terms of speed of action, 83% declared that the first signs of symptom relief appeared after 1 day of application and 78% reported full symptom resolution within 2 days of application. Additionally, ≥77% of caregivers agreed that DCO provided overnight relief from the discomfort caused by IDD and reduced sleep disturbance in their children. Finally, 85% of caregivers declared being satisfied with the product overall and considered the product pleasant to use. CONCLUSION: This evidence from caregivers' experience confirms that DCO can be considered an adequate medication to self‐manage IDD episode as it provides rapid relief of the signs and symptoms of inflammation, while by being pleasant to be use.
format Online
Article
Text
id pubmed-9817493
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98174932023-01-06 Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study Peltier, Erwan de Salvo, Raffaella Ehret, Andreas Trapp, Sonja Lakomsky, Didier El Shazly, Maged A. Health Sci Rep Original Research BACKGROUND AND AIMS: Irritant diaper dermatitis (IDD) is very common in infants and usually managed by the caregiver. Dexpanthenol‐containing ointment (DCO) is a decades‐long established product that has demonstrated efficacy and tolerability in the treatment and prevention of infant IDD in controlled clinical settings. The aim of this study was to evaluate the effectiveness of DCO in the treatment of infant IDD from the perspective of the caregiver by collecting data not explored in clinical trials, such as infant quality of life and the speed of action. METHODS: A retrospective observational real‐world data (RWD) study was conducted with French adult caregivers who had used a DCO to treat IDD in their infants within the past 6 months and consented to participate to the study completed a web‐based survey answering questions regarding the severity of their infants' symptoms (intensity/extent of redness and discomfort, rated using Likert scales) before and after DCO application. The speed of onset of symptom relief and product acceptability were also collected. RESULTS: A total of 500 caregivers of 564 infants completed the survey. Of these, 80% reported that DCO visibly treats IDD. In terms of speed of action, 83% declared that the first signs of symptom relief appeared after 1 day of application and 78% reported full symptom resolution within 2 days of application. Additionally, ≥77% of caregivers agreed that DCO provided overnight relief from the discomfort caused by IDD and reduced sleep disturbance in their children. Finally, 85% of caregivers declared being satisfied with the product overall and considered the product pleasant to use. CONCLUSION: This evidence from caregivers' experience confirms that DCO can be considered an adequate medication to self‐manage IDD episode as it provides rapid relief of the signs and symptoms of inflammation, while by being pleasant to be use. John Wiley and Sons Inc. 2023-01-06 /pmc/articles/PMC9817493/ /pubmed/36620516 http://dx.doi.org/10.1002/hsr2.1033 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Peltier, Erwan
de Salvo, Raffaella
Ehret, Andreas
Trapp, Sonja
Lakomsky, Didier
El Shazly, Maged A.
Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study
title Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study
title_full Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study
title_fullStr Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study
title_full_unstemmed Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study
title_short Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study
title_sort evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—a real‐world data observational study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817493/
https://www.ncbi.nlm.nih.gov/pubmed/36620516
http://dx.doi.org/10.1002/hsr2.1033
work_keys_str_mv AT peltiererwan evaluationofa5dexpanthenolcontainingointmentforthetreatmentofinfantirritantdiaperdermatitisthroughthelensofthecaregiverarealworlddataobservationalstudy
AT desalvoraffaella evaluationofa5dexpanthenolcontainingointmentforthetreatmentofinfantirritantdiaperdermatitisthroughthelensofthecaregiverarealworlddataobservationalstudy
AT ehretandreas evaluationofa5dexpanthenolcontainingointmentforthetreatmentofinfantirritantdiaperdermatitisthroughthelensofthecaregiverarealworlddataobservationalstudy
AT trappsonja evaluationofa5dexpanthenolcontainingointmentforthetreatmentofinfantirritantdiaperdermatitisthroughthelensofthecaregiverarealworlddataobservationalstudy
AT lakomskydidier evaluationofa5dexpanthenolcontainingointmentforthetreatmentofinfantirritantdiaperdermatitisthroughthelensofthecaregiverarealworlddataobservationalstudy
AT elshazlymageda evaluationofa5dexpanthenolcontainingointmentforthetreatmentofinfantirritantdiaperdermatitisthroughthelensofthecaregiverarealworlddataobservationalstudy